Evaluation Putting it All Together in Bipolar Disorder: Differentiating Between Bipolar 1, Bipolar 2 and Major Depressive Disorder (Module 1) Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Julie Carbray, PhD, APRN, FPMHNP-BC 5 4 3 2 1 Greg Mattingly, MD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the diagnostic challenges associated with BD, including differentiating between symptom domains as well as between BD1, BD2, and MDD 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with bipolar disorder on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage bipolar disorder. Excellent Very Good Good Fair Poor Which of the following is characteristic of manic episodes associated with BD1 but NOT hypomanic episodes associated with BD2? An unequivocal change in functioning is seen in the patient and is observable by others No marked impairment is seen in the patient The episodes are due to substance abuse The episode lasts at least 7 days, for most of the day, nearly every day Based on my participation in this activity, I anticipate I will more often: (select all that apply) Differentiate between symptom domains in patients with BD as well as BD1, BD2, and MDD Screen for past manic or hypomanic episodes in all patients with depressive symptoms Assess the impact of cardiometabolic burden on treatment adherence and overall outcomes in patients with BD Utilize novel treatment options with a lower potential for weight gain and metabolic adverse effects, such as lumateperone, in patients with BD1 and BD2 Utilize novel treatment options with a lower potential for weight gain and metabolic adverse effects, such as olanzapine + samidorphan, in patients with BD1 Utilize off-label therapies in patients with BD to mitigate weight gain Incorporate novel agents with distinct differences in MOA earlier in the treatment regimen Switch patients with weight/metabolic problems on their current treatment to a novel agent with an improved weight/metabolic profile Implement personalized strategies in routine care to minimize the rate of relapse/treatment nonadherence and improve outcomes Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
